基于肿瘤超早期免疫应答信息放大指标naCTL,TCR/BCR/HLA有效多样性等免疫信息学多维指标的中医(肿瘤)治未病测知、评价模型(体系)构建

Traditional Chinese medicine (tumor) prevention and evaluation model based on ultra-early immune response information amplification index naCTL and multidimensional immunoinformatic index TCR/BCR/HLA effective diversity

肿瘤细胞在形成瘤体前(超早期)是干预最佳时期,但限于该时期肿瘤细胞数量,当前主要针对其本身的检测(如CTC,ct DNA等)难以实现肿瘤细胞与免疫力的量化,这不仅无法实现该时期精准预防,也影响中医(肿瘤)治未病深入测知、干预、评价。鉴于当前检测局限性,该评价体系转而检测与肿瘤细胞直接相关的、经其激活、增殖至高数量级的肿瘤新生抗原特异性细胞毒性T淋巴细胞(naCTL),免疫组有效性多样性(TCR/BCR/HLA在递呈、识别肿瘤新生抗原上的有效多样性),并引入免疫检查点(check point)、中医病证(治未病)信息等,运用多种数据分析及相关算法,建立免疫正常化多维统计模型。该体系充分放大肿瘤超早期信息,同时,深度融合中医整体观、平衡观思想与扶正祛邪基本治则,为机体免疫正常化及中医(肿瘤)治未病提供量化测知、评价新方法,也为中医证候科学内涵与中药复方药效评价提供新思路,新方法。

The best time of tumor intervention is before the formation of tumor.However,due to the limited number of tumor cells,it is difficult to quantify tumor cells and immunity by the current methods available(such as CTC,ct DNA).This affects the tumor prevention in this period,and the in-depth detection,intervention and evaluation of traditional Chinese medicine(TCM)(tumor)prevention.Due to the limitations of the current detection,the evaluation system turns to detect tumor neoantigen-specific CTL(naCTL)that are directly relating to tumor cells and proliferate to high order of magnitudes after activation,and immune repertoire(TCR/BCR/HLA)effective diversity,introduces immune checkpoints,uses information of'disease'in Western medicine and'syndrome'in TCM(prevention),and sets up a multi-dimensional statistical immunity model using a variety of data analysis and related algorithms.This model can amplify the ultra-early information of tumor,indirectly evaluate the quantity and status of tumor cells,and provide quantitative measurement and new evaluation methods for the normalization of immunity and TCM(tumor)prevention.This model is not only one of important evaluation methods for resisting tumor immunity and treating TCM(tumor)prevention,but also will reveal the scientific connotation of TCM syndrome from the perspective of immunology.